Your company is already operating in Germany and you would now like to export worldwide?
Investment in biotechnology is surging globally and Germany — the fourth largest pharma market in the world — excels in the field. Every year it attracts more international investors and companies to fund the development of new medicines and vaccines.
A multi-billion-dollar deal for German company BioNTech is the latest indication of the central role Europe’s largest economy plays in attempts to cure the deadly disease.
Germany’s healthcare sector is attracting more VC investment as it enters the digital age. Electronic patient records are being rolled out and generative AI tools supporting the medical product approval process assessed.
Data on publicly insured patients will now automatically be registered electronically unless those concerned opt out.
Financing for companies in Germany rose markedly in 2024, with interest particularly strong in cancer treatments.
American pharmaceutical giant Eli Lilly is radically expanding its presence in Germany.
That’s great news for the country, which sees biotech and pharmaceuticals as one of its
main pillars for the years to come.
Germany’s healthcare sector is benefiting from major investments in new gene and cell therapy research and development sites.
The pharmaceuticals and chemicals giant is investing a hefty nine-figure in a state-of-the-art facility in its home city of Darmstadt.
AbbVie is building an ultra-modern research and office facility in the western German city of Ludwigshafen.
The High-Tech Gründerfonds (HTGF) will sell its shares in start-up Cardior Pharmaceuticals as part of a billion-euro acquisition by industry giant Novo Nordisk.
